IGI Logo

Dr. Reddy's Laboratories is currently trading at Rs. 6135.95, up by 88.35 points or 1.46% from its previous closing of Rs. 6047.60 on the BSE.

The scrip opened at Rs. 6096.35 and has touched a high and low of Rs. 6185.00 and Rs. 6081.75 respectively. So far 4744 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 6505.50 on 28-Feb-2024 and a 52 week low of Rs. 4383.40 on 19-May-2023.

Last one week high and low of the scrip stood at Rs. 6299.70 and Rs. 6035.50 respectively. The current market cap of the company is Rs. 103010.28 crore.

The promoters holding in the company stood at 26.65%, while Institutions and Non-Institutions held 47.27% and 10.75% respectively.

Dr. Reddy's Laboratories has entered into an exclusive partnership with Sanofi Healthcare India (SHIPL) to promote and distribute their vaccine brands across private markets in India. Under the arrangement, Dr. Reddy’s will have exclusive rights to promote and distribute Sanofi’s well established and trusted paediatric and adult vaccine brands Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri, Adacel and Avaxim 80U. These brands saw combined sales of around Rs 426 crore as per IQVIA MAT February 2024. Sanofi will continue to own, manufacture, and import these brands to the country.    

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.